Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2021 Publisher: GlaxoSmithKline UK Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom
Dectova 10 mg/mL solution for infusion.
| Pharmaceutical Form |
|---|
|
Solution for infusion. A clear, colourless solution for infusion. |
Each mL of solution contains 10 mg of zanamivir (as hydrate).
Each vial contains 200 mg of zanamivir (as hydrate) in 20 mL.
Excipients with known effect:
Each vial contains 3.08 mmol (70.8 mg) sodium.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Zanamivir |
Zanamivir is a selective inhibitor of neuraminidase, the influenza virus surface enzyme. Neuraminidase inhibition occurred in vitro at very low zanamivir concentrations (50% inhibition at 0.64nM–7.9nM against influenza A and B strains). |
| List of Excipients |
|---|
|
Sodium chloride |
26 mL clear vial (type I glass) with a stopper (coated chlorobutyl rubber), an over-seal (aluminium) and a plastic flip-off cap.
Pack size: 1 vial.
GlaxoSmithKline UK Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom
PLGB 19494/0292
Date of first authorisation: 01/01/2021
| Drug | Countries | |
|---|---|---|
| DECTOVA | Austria, Estonia, Finland, France, Croatia, Ireland, Lithuania, Netherlands, Poland, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
